ArticleScientific reports2025
Role of metabolomic changes in diagnosis and assessment of treatment response in acute myeloid leukemia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Boosting CAR T cell efficacy in cancer with metabolic insights from design to diet.Nature reviews. Cancer · 2026Review
- Inclusion of Multi-Omic Biomarkers Improves Prediction Accuracy of Response, Relapse, and Overall Survival in Acute Myeloid Leukemia Patients Receiving High-Intensity Induction Chemotherapy.Cancer medicine · 2026Article
- NMR-based metabolomics analysis in breast cancer patients from Saudi Arabia: a pilot study.Scientific reports · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute Myeloid Leukemia (AML) is an aggressive cancer characterized by the rapid proliferation of abnormal myeloid cells. Despite advancements in treatment, patient outcomes remain variable, underscoring the need for more accurate diagnostic and prognostic tools. Metabolomics has gained attention for its potential to offer new insights into disease mechanisms and progression. This study aimed to compare metabolomic profiles between AML patients and normal controls, determine the diagnostic accuracy of different metabolites in AML patients, assess the diagnostic accuracy of specific metabolites in AML patients, and evaluate the prognostic significance of these metabolites at the first bone marrow follow-up. The cross-sectional study included 56 AML patients (sampled before and after chemotherapy) and 56 age- and sex-matched healthy controls. Whole blood and serum samples were collected from all participants after obtaining informed consent. Metabolomic analysis was performed using a Bruker 600 MHz NMR spectrometer. Results revealed significant metabolic alterations between AML patients and healthy controls, as well as in remission and non-remission groups. Key disrupted pathways included lipid metabolism, amino acid metabolism, and glycolysis (p < 0.05). Metabolite panels such as acetate, creatine, and lactate demonstrated strong diagnostic potential (AUC = 0.98), while citrate, glutamate, and choline panels (AUC = 0.89) showed prognostic utility in distinguishing patients from controls and remission from non-remission groups, respectively (p < 0.05). The study highlights significant metabolomic alterations in AML patients, marked by disruptions in lipid, energy, and amino acid metabolism, elevated glucose levels, and enhanced diagnostic and prognostic capabilities. These findings support the development of personalized diagnostic and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.